CLINICAL TRIALS PROFILE FOR ERLEADA
✉ Email this page to a colleague
All Clinical Trials for erleada
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02366494 ↗ | Micro RNAs to Predict Response to Androgen Deprivation Therapy | Active, not recruiting | Medical College of Wisconsin | 2015-04-29 | Identify exosomal micro RNA that predict responses to ADT | |
| NCT03009981 ↗ | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | Recruiting | Janssen Research & Development, LLC | Phase 3 | 2017-03-06 | This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry. |
| NCT03009981 ↗ | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | Recruiting | Alliance Foundation Trials, LLC. | Phase 3 | 2017-03-06 | This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry. |
| NCT03279250 ↗ | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | Completed | Janssen Scientific Affairs, LLC | Phase 2 | 2017-10-13 | This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer. |
| NCT03279250 ↗ | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | Completed | M.D. Anderson Cancer Center | Phase 2 | 2017-10-13 | This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery. Apalutamide and abiraterone acetate may stop the growth of cancer cells either by killing the cells or by blocking some of the enzymes needed for cell growth. Hormone therapy, using gonadotropin-releasing hormone analog, may fight prostate cancer by lowering the amount of testosterone the body makes. Giving apalutamide, gonadotropin-releasing hormone analog, and abiraterone acetate may work better in treating participants with prostate cancer. |
| NCT03360721 ↗ | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | Suspended | Janssen Scientific Affairs, LLC | Phase 2 | 2018-03-06 | This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as prednisone, is used to decrease the body's immune response and may improve bone marrow function. Giving apalutamide, abiraterone acetate, and prednisone may work better in treating participants with castration resistant prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for erleada
Condition Name
Clinical Trial Locations for erleada
Trials by Country
Clinical Trial Progress for erleada
Clinical Trial Phase
Clinical Trial Sponsors for erleada
Sponsor Name
